CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities

British Journal of Pharmacology

Volumn 144, Issue 7, 2005, Pages 1002-1010

  Trifilieff, Alexandre ^a   Keller, Thomas H ^a   Press, Neil J ^a   Howe, Trevor ^a   Gedeck, Peter ^a   Beer, David ^a   Walker, Christoph ^a  

^a Novartis Inst of BioMedical Res   (United Kingdom)

Author keywords

Adenosine receptor; Asthma; Chronic obstructive pulmonary disease; p38MAP kinase; Phosphodiesterase

Indexed keywords

2 AMINO 4 (3,4 DICHLOROPHENYL) 5 PYRIDIN 4 YL THIAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CGH 2466; CILOMILAST; CYCLOSPORIN A; CYTOKINE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 BETA; OVALBUMIN; OXYGEN RADICAL; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; THEOPHYLLINE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IC 50; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, PURINERGIC P1; THIAZOLES;

EID: 17844365897     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706132     Document Type: Article

References (41)

1. BARNES, P.J. (1997), Current therapies for asthma. Promise and limitations. Chest, 111, 17S-26S.
2. BARNES, P.J. (2003). Theophylline: new perspectives for an old drug. Am. J. Respir. Crit. Care Med., 167, 813-818.
3. BARNES, P.J., PEDERSEN, S. & BUSSE, W.W. (1998). Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med., 157, S1-S53.
4. BERMAN, H.M., WESTBROOK, J., FENG, Z., GILLILAND, G., BHAT, T.N., WEISSIG, H., SHINDYALOV, I.N. & BOURNE, P.E. (2000). The protein data bank. Nucleic Acids Res., 28, 235-242.
5. BOEHM, J.C., SMIETANA, J.M., SORENSON, M.E., GARIGIPATI, R.S., GALLAGHER, T.F., SHELDRAKE, P.L., BRADBEER, J., BADGER, A.M., LAYDON, J.T., LEE, J.C., HILLEGASS, L.M., GRISWOLD, D.E., BRETON, J.J., CHABOT-FLETCHER, M.C. & ADAMS, J.L. (1996). 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Chem., 39, 3929-3937.
6. CHRISTENSEN, S.B., GUIDER, A., FORSTER, C.J., GLEASON, J.G., BENDER, P.E., KARPINSKI, J.M., DEWOLF JR, W.E., BARNETTE, M.S., UNDERWOOD, D.C., GRISWOLD, D.E., CIESLINSKI, L.B., BURMAN, M., BOCHNOWICZ, S., OSBORN, R.R., MANNING, C.D., GROUS, M., HILLEGAS, L.M., BARTUS, J.O., RYAN, M.D., EGGLESTON, D.S., HALTIWANGER, R.C. & TORPHY, T.J. (1998). 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J. Med. Chem., 41, 821-835.
7. CORTELING, R., WYSS, D. & TRIFILIEFF, A. (2002). In vivo models of lung neutrophil activation. Comparison of mice and hamsters. BMC Pharmacol., 2, 1.
8. ENGELS, P., SULLIVAN, M., MULLER, T. & LUBBERT, H. (1995). Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett., 358, 305-310.
9. ESCOTT, K.J., BELVISI, M.G., BIRRELL, M.A., WEBBER, S.E., FOSTER, M.L. & SARGENT, C.A. (2000), Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat. Br. J. Pharmacol., 131, 173-176,
10. EVANS, D.J., TAYLOR, D.A., ZETTERSTROM, O., CHUNG, K.F., O'CONNOR, B.J. & BARNES, P.J. (1997). A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N. Engl. J. Med., 337, 1412-1418.
11. FEOKTISTOV, I., POLOSA, R., HOLGATE, S.T. & BIAGGIONI, I. (1998). Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol. Sci., 19, 148-153.
12. FOZARD, J.R. & HANNON, J.P. (2000). Species differences in adenosine receptor-mediated bronchoconstrictor responses. Clin. Exp. Allergy, 30, 1213-1220.
13. FOZARD, J.R. & MCCARTHY, C. (2002). Adenosine receptor ligands as potential therapeutics in asthma. Curr. Opin. Investig. Drugs, 3, 69-77.
14. GAMBLE, E., GROOTENDORST, D.C., BRIGHTLING, C.E., TROY, S., QIU, Y., ZHU, J., PARKER, D., MATIN, D., MAJUMDAR, S., VIGNOLA, A.M., KROEGEL, C., MORELL, F., HANSEL, T.T., RENNARD, S.I., COMPTON, C., AMIT, O., TAT, T., EDELSON, J., PAVORD, I.D., RABE, K.F., BARNES, N.C. & JEFFERY, P.K. (2003). Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 168, 976-982.
15. GRISWOLD, D.E., WEBB, E.F., BADGER, A.M., GORYCKI, P.D., LEVANDOSKI, P.A., BARNETTE, M.A., GROUS, M., CHRISTENSEN, S. & TORPHY, T.J. (1998). SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo. J. Pharmacol. Exp. Ther., 287, 705-711.
16. HANNON, J.P., TIGANI, B., WOLBER, C., WILLIAMS, I., MAZZONI, L., HOWES, C. & FOZARD, J.R. (2002). Evidence for an atypical receptor mediating the augmented bronchoconstrictor response to adenosine induced by allergen challenge in actively sensitized Brown Norway rats. Br. J. Pharmacol., 135, 685-696.
17. HERLAAR, E. & BROWN, Z. (1999). p38 MAPK signalling cascades in inflammatory disease. Mol. Med. Today, 5, 439-447.
18. IWAMURA, H., SUZUKI, H., UEDA, Y., KAYA, T. & INABA, T. (2001). In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB(2) receptor. J. Pharmacol. Exp. Ther., 296, 420-425.
19. JEFFERY, P.K. (2000). Comparison of the structural and inflammatory features of COPD and asthma, Giles F. Filley Lecture. Chest, 117, 251-260.
20. KIM, Y.C., DE ZWART, M., CHANG, L., MORO, S., VON FRIJTAG DRABBE KUNZEL, J.K., MELMAN, N., IJZERMAN, A.P. & JACOBSON, K.A. (1998). Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. J. Med. Chem., 41, 2835-2845.
21. KLOTZ, K.N. (2000). Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch. Pharmacol., 362, 382-391.
22. KOHNO, Y., JI, X., MAWHORTER, S.D., KOSHIBA, M. & JACOBSON, K.A. (1996). Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood, 88, 3569-3574.
23. LAPPE, R.W., SHELDON, J.H. & COX, B.F. (1992). Selective adenosine-2 agonist produces both direct and reflex tachycardia in normotensive rats. J. Cardiovasc. Pharmacol., 19, 460-463.
24. PAGE, C.P. (1999). Recent advances in our understanding of the use of theophylline in the treatment of asthma. J. Clin. Pharmacol., 39, 237-240.
25. RABE, K.F. & DENT, G. (1998). Theophylline and airway inflammation. Clin. Exp. Allergy, 28 (Suppl 3), 35-41.
26. REVESZ, L., DI PADOVA, P.E., BUHL, T., FEIFEL, R., GRAM, H., HIESTAND, P., MANNING, U. & ZIMMERLIN, A.G. (2000). SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. Bioorganic Med. Chem. Lett., 10, 1261-1264.
27. ROBICHAUD, A., STAMATIOU, P.B., JIN, S.L.C., LACHANCE, N., MACDONALD, D., LALIBERTE, F., LIU, S., HUANG, Z., CONTI, M. & CHAN, C.C. (2002). Deletion of phosphodiesterase 4D in mice shortens {alpha}2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest., 110, 1045-1052.
28. SOUZA, D.O., CASSALI, G.D., POOLE, S. & TEIXEIRA, M.M. (2001). Effects of inhibition of PDE4 and TNF-α on local and remote injuries following ischaemia and reperfusion injury. Br. J. Pharmacol., 134, 985-994.
29. TEIXEIRA, M.M., GRISTWOOD, R.W., COOPER, N. & HELLEWELL, P.G. (1997). Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci., 18, 164-171.
30. THOMAS, T., ST LAMBERT, J.H., DASHWOOD, M.R. & SPYER, K.M. (2000). Localization and action of adenosine A2a receptors in regions of the brainstem important in cardiovascular control. Neuroscience, 95, 513-518.
31. TORPHY, T.J. (1998). Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med., 157, 351-370.
32. TRIFILIEFF, A., EL-HASHIM, A. & BERTRAND, C. (2000). Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment. Am. J. Physiol. Lung Cell. Mol. Physiol., 279, L1120-L1128.
33. TRIFILIEFF, A., WYSS, D., WALKER, C., MAZZONI, L. & HERSPERGER, R. (2002). Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE 171), a 1,7-naphthyridine derivative, with anti-inflammatory activities. J. Pharmacol. Exp. Ther., 301, 241-248.
34. UNDERWOOD, D.C., OSBORN, R.R., KOTZER, C.J., ADAMS, J.L., LEE, J.C., WEBB, E.F., CARPENTER, D.C., BOCHNOWICZ, S., THOMAS, H.C., HAY, D.W. & GRISWOLD, D.E. (2000). SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J. Pharmacol. Exp. Ther., 293, 281-288.
35. VANGREVELINGHE, E., ZIMMERMANN, K., SCHOEPFER, J., PORTMANN, R., FABBRO, D. & FURET, P. (2003). Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem., 46, 2656-2662.
36. WANG, Z., CANAGARAJAH, B.J., BOEHM, J.C., KASSISA, S., COBB, M.H., YOUNG, P.R., ABDEL-MEGUID, S., ADAMS, J.L. & GOLDSMITH, E.J. (1998). Structural basis of inhibitor selectivity in MAP kinases. Structure, 6, 1117-1128.
37. WILSON, K.P., FITZGIBBON, M.J., CARON, P.R., GRIFFITH, J.P., CHEN, W., MCCAFFREY, P.G., CHAMBERS, S.P. & SU, M.S. (1996). Crystal structure of p38 mitogen-activated protein kinase. J. Biol. Chem., 271, 27696-27700.
38. WILSON, K.P., MCCAFFREY, P.G., HSIAO, K., PAZHANISAMY, S., GALULLO, V., BEMIS, G.W., FITZGIBBON, M.J., CARON, P.R., MURCKO, M.A. & SU, M.S. (1997). The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol., 4, 423-431.
39. XU, R.X., HASSELL, A.M., VANDERWALL, D., LAMBERT, M.H., HOLMES, W.D., LUTHER, M.A., ROCQUE, W.J., MILBURN, M.V., ZHAO, Y., KE, H. & NOLTE, R.T. (2000). Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science, 288, 1822-1825.
40. YASUI, K., AGEMATSU, K., SHINOZAKI, K., HOKIBARA, S., NAGUMO, H., NAKAZAWA, T. & KOMIYAMA, A. (2000). Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J. Leukoc. Biol., 67, 529-535.
41. ZUSSMAN, B.D., BENINCOSA, L.J., WEBBER, D.M., CLARK, D.J., COWLEY, H., KELLY, J., MURDOCH, R.D., UPWARD, J., WYLD, P., PORT, A. & FUDER, H. (2001). An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. J. Clin. Pharmacol., 41, 950-958.